Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUAIL-100 in High-Risk Acute Leukemia and Myelodysplastic Syndrome Post-HSCT
NCT07573111Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LGNA-100 in acute leukemia and myelodysplastic syndrome (MDS). Primary endpoint: Incidence of treatment-emergent adverse events at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
LGNA-100
03
Conditions
acute leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07573111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573111.